FP7Индивидуална стипендия2010–2012

MIRNA MECHANISM · In-vitro system for mammalian miRNA function

7РП — „Хора“ (Действия „Мария Кюри“)

Период
2010-04-01 → 2012-03-31
Финансиране от ЕС
159 661 €
Участници
1
Схема
MC-IIF

Линиите свързват координатора с партньорите.

Накратко на български

МикроРНК молекулите регулират работата на гените, като например потискат синтеза на протеини чрез взаимодействие с опашката на иРНК. Разбирането на този механизъм помага да се изясни как се развиват заболявания като рака.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

In-vitro system for mammalian miRNA function

Results and Conclusions: microRNAs (miRNAs) have been implicated in a broad range of diseases, such as the development and progression of cancer. miRNAs are small RNAs that post-transcriptionally regulate gene expression in eukaryotes. In animals, miRNAs bind to complementary sites in messenger RNAs (mRNAs), causing translational repression and mRNA deadenylation and degradation. It has been proposed that miRNAs inhibit translation during the initiation phase of protein synthesis. However, the precise molecular mechanism is still unknown. This study has shed light on the interplay between miRNAs and the translation initiation machinery. mRNAs bearing a poly(A) tail are typically more strongly repressed by miRNAs than their counterparts lacking this 3' modification. Using a Drosophila cell-free system, we analyzed the role of the poly(A)-tail in miRNA-mediated repression in detail. We show that repression increases with an extension of the poly(A)-tail and that the poly(A)-tail contribution to miRNA-mediated repression occurs independently of the number of miRNA-binding sites in the mRNA. We demonstrate that this effect is mediated by the poly(A)-binding protein PABP, since poly(A)-tail contribution is lost in PABP-depleted extracts and can be rescued by addition of recombinant PABP. miRNAs function as part of ribonucleoprotein complexes, miRNPs, with Argonaute (Ago) and GW182 family proteins being the crucial components. The functional regions of GW182 have been mapped and it was shown that tethering the silencing domain (SD) of GW182 to an mRNA causes repression. We show here that tethering GW182-SD faithfully recapitulates all the hallmarks of miRNA-mediated repression in vitro. However, when translation is repressed by GW182-SD tethering rather than by miRISC itself, the stimulatory poly(A) effect is lost. Contrary to current models in which the micro RNA-induced silencing complex (miRISC) interferes with a positive function of PABP in translation, we show that repression positively correlates with poly(A) tail length. These findings are explained by a novel role of PABP as a co-repressor that facilitates the specific association of miRISC with microRNA-regulated mRNAs. Furthermore, we provide evidence that PABP is displaced from a repressed RNA and that this displacement is an early event, which is further enhanced by deadenylation of the target RNA. Therefore, the work which was funded by this fellowship has provided an important¬¬ conceptual advancement in form of a revised model (see Figure 1) for the function of PABP and the poly(A) tail in micro RNA-mediated translational repression. Socio-Economic Impact: This research project has a wide-range implication beyond gene regulation with an undeniable socio-economic significance for human health. miRNAs have been implicated in the establishment of various human diseases, such as cancer. However, the molecular mechanism by which they inhibit target gene expression is still incompletely understood, thereby stalling the development of novel diagnostic and therapeutic strategies. Our work has shed light on the interplay of miRISC with the pivotal translation initiation factor PABP. Thus, our work has enhanced our understanding of the fundamental molecular mechanism of miRNAs, and this in the long-term will extend the potential development of pharmaceutical applications to target diseases with aberrant miRNA function.

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

Over the past decade, micro (mi) RNAs have emerged as key regulators of gene expression. Many miRNAs have been linked to diseases, such as cancer or diabetes. MiRNAs bind to specific sequences in the 3’-untranslated region (UTR) of mRNAs, thereby causing inhibition of translation and/or mRNA degradation. However, the detailed molecular mechanism and the factors involved in miRNA-mediated gene silencing are still incompletely understood. The primary research objective of the current proposal is the generation of a novel mammalian in-vitro system that will allow a detailed biochemical dissection of the molecular mechanisms underlying medical relevant miRNA-guided gene silencing. In particular, we will characterize repression mediated by the tumorsuppressor miRNA let-7. We will elucidate the role of cis- and trans-acting factors in miRNA mediated repression and use the system to purify native miRISC-RNP-complexes (Ribonucleoprotein-complexes) and subsequently identify and characterize the components of the complex. Thus, the knowledge gained from this proposal will enhance our understanding of miRNA function and provide novel insights into the role of RNA metabolism in disease, which will be applicable to the development of novel diagnostic and therapeutic strategies targeting miRNA-associated pathologies.

Оригинален текст от CORDIS (на английски).

Участници

  • EUROPEAN MOLECULAR BIOLOGY LABORATORY · HeidelbergКоординаторГермания

Връзки

Данни: CORDIS, © Европейски съюз